Printer Friendly

BIO-RAD ANNOUNCES CLEARANCE OF LIFE SCIENCE AND DIAGNOSTICS GROUPS TO CONTINUE FEDERAL CONTRACTS

 HERCULES, Calif., June 18 /PRNewswire/ -- Bio-Rad (AMEX: BIO.A, BIO.B) announced today that the General Services Administration (GSA) terminated debarment proceedings for its Life Science and Diagnostics groups and that these businesses will be allowed to resume their contract activities with all United States Government entities. The GSA also informed the company that it will be extending the time for its investigation into the proposed debarment of the Analytical Instruments group which represents less than 20 percent of Bio-Rad's worldwide revenues. This releases the majority of the company to conduct its business with the federal government without any restrictions. Management believes that settlement of the remaining issues will not have a material impact on the financial position of the company.
 Bio-Rad Laboratories is a multinational manufacturer of life science research products, clinical diagnostics and analytical instruments based in Hercules.
 -0- 6/18/93
 /CONTACT: James L. Viglienzone, treasurer of Bio-Rad, 510-724-5697/
 (BIO.A BIO.B)


CO: Bio-Rad Laboratories Inc.; General Services Administration ST: California IN: MTC SU:

TM-SG -- SF004 -- 3414 06/18/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 18, 1993
Words:177
Previous Article:IDB COMMUNICATIONS AND TELECOM NEW ZEALAND INTERNATIONAL SIGN AGREEMENT FOR INTERNATIONAL TELEPHONE SERVICE
Next Article:MICRONICS FACILITATES DEVELOPMENT OF 'GREEN PCs'; NEW PRODUCTS PROVIDE ABILITY TO MEET OR EXCEED NEW GOVERNMENT REGULATIONS
Topics:


Related Articles
BIO-RAD ANNOUNCES SECOND QUARTER SALES AND EARNINGS
JAMES BENNETT APPOINTED CHIEF OPERATING OFFICER OF BIO-RAD
BIO-RAD ANNOUNCES FULL CLEARANCE BY GSA
Bio-Rad and Chiron Finalize the Purchase and Sale of Chiron's Quality Controls Business
Bio-Rad Laboratories and Saigene Corporation Enter Into a Worldwide Exclusive Licensing Agreement to Commercialize Genes Associated With...
Bio-Rad Laboratories and Axis-Shield Group Sign Exclusive Licensing Agreement.
Bio-Rad, Sanofi-Synthelabo and Institut Pasteur Sign Definitive Agreement for the Acquisition of Pasteur Sanofi Diagnostics.
Bio-Rad's Aspergillus EIA Test Kit Receives FDA 510(k) Clearance; Sensitive, Non-Invasive Test Simplifies and Speeds Up Diagnostic Process, Reduces...
Bio-Rad Announces Management Transition.
Bio-Rad Receives FDA Clearance for New BioPlex(R) 2200 System.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters